等待開盤 08-15 09:30:00 美东时间
0.000
0.00%
Dave (NASDAQ:DAVE) announced on Wednesday an increase to its share repurchase authorization to $125M, replacing the $50M program announced on March 10. The company said it has deployed ~$25M to repurc...
08-13 20:23
Dave Inc. increased its stock repurchase authorization to $125 million, up from $50 million, as part of its disciplined capital allocation strategy. Since its Q2 earnings announcement on August 6, Dave has repurchased approximately $25 million worth of shares, with total year-to-date repurchases and RSU net settlements exceeding $45 million. Kyle Beilman, COO and CFO, expressed confidence in Dave's positive outlook and strong business model. The ...
08-13 12:00
This whale alert can help traders discover the next big trading opportunities. ...
08-12 01:35
In the latest quarter, 9 analysts provided ratings for Dave (NASDAQ:DAVE), show...
08-08 02:02
JMP Securities analyst Devin Ryan maintains Dave (NASDAQ:DAVE) with a Market Outperform and raises the price target from $260 to $280.
08-07 21:25
Dave shares are trading lower after the company reported a Q2 EPS miss.
08-06 23:19
Dave (NASDAQ:DAVE) reported quarterly earnings of $3.14 per share which beat the analyst consensus estimate of $1.65 by 90.53 percent. This is a 210.89 percent increase over earnings of $1.01 per share from the same
08-06 20:09
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
今日重点评级关注:花旗:维持Apellis Pharmaceuticals"买入"评级,目标价从41美元升至46美元;杰富瑞:维持Kiniksa Pharmaceuticals"买入"评级,目标价从45美元升至54美元
07-30 09:36
12 analysts have shared their evaluations of Dave (NASDAQ:DAVE) during the rece...
07-30 03:00